Ekso Bionics Holdings (NASDAQ: EKSO) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Volatility and Risk

Ekso Bionics Holdings has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, Strata Skin Sciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Profitability

This table compares Ekso Bionics Holdings and Strata Skin Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ekso Bionics Holdings -372.20% -798.93% -146.30%
Strata Skin Sciences -18.00% -41.58% -13.22%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ekso Bionics Holdings and Strata Skin Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ekso Bionics Holdings 0 0 2 0 3.00
Strata Skin Sciences 0 0 2 0 3.00

Ekso Bionics Holdings presently has a consensus target price of $6.00, suggesting a potential upside of 380.00%. Strata Skin Sciences has a consensus target price of $12.00, suggesting a potential upside of 597.67%. Given Strata Skin Sciences’ higher probable upside, analysts plainly believe Strata Skin Sciences is more favorable than Ekso Bionics Holdings.

Insider & Institutional Ownership

6.0% of Ekso Bionics Holdings shares are owned by institutional investors. Comparatively, 24.1% of Strata Skin Sciences shares are owned by institutional investors. 7.1% of Ekso Bionics Holdings shares are owned by company insiders. Comparatively, 12.9% of Strata Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Ekso Bionics Holdings and Strata Skin Sciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Ekso Bionics Holdings $7.49 million 4.30 -$27.14 million ($1.55) -0.81
Strata Skin Sciences $32.37 million 0.13 $5.87 million ($2.70) -0.64

Strata Skin Sciences has higher revenue and earnings than Ekso Bionics Holdings. Ekso Bionics Holdings is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Strata Skin Sciences beats Ekso Bionics Holdings on 9 of the 11 factors compared between the two stocks.

Ekso Bionics Holdings Company Profile

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation to develop products for military applications, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.

Strata Skin Sciences Company Profile

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.